The global anti-obesity drugs market size reached USD 2.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.9 Billion by 2033, exhibiting a growth rate (CAGR) of 9.89% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 2.5 Billion |
Market Forecast in 2033
|
USD 5.9 Billion |
Market Growth Rate (2025-2033) | 9.89% |
Anti-obesity drugs are intended to reduce or control weight and generally medically prescribed only in cases of morbid obesity. They help reduce cravings and control compulsive eating, especially for sweets and fatty, salty, and high-calorie food products. They can also provide independent health benefits, such as controlling blood pressure, harmful lipid levels, waist circumference, sugar levels and nonalcoholic fatty liver disease (NAFLD) and minimize the risk of major cardiovascular diseases (CVDs) and progression of diabetic kidney disease.
Recent advances in anti-obesity drugs have enabled the potential of attaining clinically significant weight loss among individuals. This, in confluence with the widespread prevalence of obesity on account of sedentary lifestyles, represents one of the key factors creating a positive outlook for the market. In addition, obesity increases the risk of developing type 2 diabetes (T2D), cardiovascular diseases (CVD), and cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney. It can also result in numerous psychological, neurological, pulmonary, gastrointestinal, renal, musculoskeletal, and endocrine diseases. Besides this, sleep deprivation, circadian desynchronization, chronic stress, and the rising use of anti-epileptic and psychotropic drugs may further induce weight gain. This, coupled with the increasing number of approvals of anti-obesity medications (AOMs) that help regulate appetite and food cravings, is fueling the growth of the market. Apart from this, weight loss aids in improving the quality of life, mobility, daily function, and psychological well-being of individuals. This, along with the increasing health consciousness, thriving pharmaceutical industry, and the rising focus on the management of diseases closely integrated with excess body weight, is anticipated to stimulate the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-obesity drugs market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on drug class, drug type, and distribution channel.
Breakup by Drug Class:
Breakup by Drug Type:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Drug Class, Drug Type, Distribution Channel, Region |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global anti-obesity drugs market was valued at USD 2.5 Billion in 2024.
We expect the global anti-obesity drugs market to exhibit a CAGR of 9.89% during 2025-2033.
The rising demand for anti-obesity drugs for weight loss and to regulate food cravings that help in improving the quality of life, mobility, daily function, etc., is primarily driving the global anti-obesity drugs market.
The sudden outbreak of the COVID-19 pandemic has led to the rising demand for anti-obesity drugs, owing to the immediate weight gain occurred among the individuals during sit-home or Work-From-Home (WFH) scenario.
Based on the drug class, the global anti-obesity drugs market can be segmented into peripherally acting drugs and centrally acting drugs. Currently, centrally acting drugs hold the majority of the total market share.
Based on the drug type, the global anti-obesity drugs market has been divided into prescription drugs and OTC drugs, where prescription drugs currently exhibit a clear dominance in the market.
Based on the distribution channel, the global anti-obesity drugs market can be categorized into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, hospital pharmacy accounts for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global anti-obesity drugs market include Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited, and Vivus LLC.